$14.51
0.89% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Arcutis Biotherapeutics Inc Stock price

$14.51
+0.98 7.24% 1M
+4.33 42.53% 6M
+0.58 4.16% YTD
+5.16 55.19% 1Y
-6.15 29.77% 3Y
-14.70 50.33% 5Y
-7.29 33.44% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.13 0.89%
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Key metrics

Market capitalization $1.73b
Enterprise Value $1.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.71
P/S ratio (TTM) P/S ratio 8.13
P/B ratio (TTM) P/B ratio 12.12
Revenue growth (TTM) Revenue growth 100.03%
Revenue (TTM) Revenue $212.82m
EBIT (operating result TTM) EBIT $-121.30m
Free Cash Flow (TTM) Free Cash Flow $-111.69m
Cash position $198.71m
EPS (TTM) EPS $-1.04
P/E forward negative
P/S forward 5.57
EV/Sales forward 5.29
Short interest 15.71%
Show more

Is Arcutis Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Arcutis Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

Buy
100%

Financial data from Arcutis Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
213 213
100% 100%
100%
- Direct Costs 25 25
203% 203%
12%
188 188
91% 91%
88%
- Selling and Administrative Expenses 233 233
20% 20%
110%
- Research and Development Expense 71 71
28% 28%
33%
-116 -116
41% 41%
-54%
- Depreciation and Amortization 5.37 5.37
236% 236%
3%
EBIT (Operating Income) EBIT -121 -121
38% 38%
-57%
Net Profit -130 -130
40% 40%
-61%

In millions USD.

Don't miss a Thing! We will send you all news about Arcutis Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcutis Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
6 days ago
Arcutis announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients.
Neutral
GlobeNewsWire
14 days ago
Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy 66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global Assessment (S-IGA) Success at Week 8 45.5% of individuals treated with ZORYVE foam achieved Body-Investigator Global Assessment (B-IGA) Success at Week 8 Efficacy and safety res...
Neutral
Seeking Alpha
14 days ago
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Amanda Sheldon - Head of Corporate Communications Frank Watanabe - President and CEO Todd Edwards - CCO Patrick Burnett - Chief Medical Officer Latha Vairavan - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear -...
More Arcutis Biotherapeutics Inc News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.

Head office United States
CEO Todd Watanabe
Employees 342
Founded 2016
Website www.arcutis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today